Oramed Pharmaceuticals Inc.

NasdaqCM:ORMP Stock Report

Market Cap: US$91.1m

Oramed Pharmaceuticals Valuation

Is ORMP undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of ORMP when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate ORMP's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate ORMP's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for ORMP?

Key metric: As ORMP is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for ORMP. This is calculated by dividing ORMP's market cap by their current earnings.
What is ORMP's PE Ratio?
PE Ratio20.9x
EarningsUS$4.47m
Market CapUS$91.11m

Price to Earnings Ratio vs Peers

How does ORMP's PE Ratio compare to its peers?

The above table shows the PE ratio for ORMP vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average15x
IBO Impact BioMedical
25.9xn/aUS$30.5m
PROC Procaps Group
2.4xn/aUS$64.5m
BTMD biote
26.6x64.8%US$220.2m
SIGA SIGA Technologies
5.2xn/aUS$446.3m
ORMP Oramed Pharmaceuticals
20.9x-163.0%US$91.1m

Price-To-Earnings vs Peers: ORMP is expensive based on its Price-To-Earnings Ratio (20.9x) compared to the peer average (15x).

Price to Earnings Ratio vs Industry

How does ORMP's PE Ratio compare vs other companies in the US Pharmaceuticals Industry?

12 CompaniesPrice / EarningsEstimated GrowthMarket Cap
OGN Organon
2.9x-7.1%US$3.79b
NDOI Endo
0.6xn/aUS$1.91b
PROC Procaps Group
2.4xn/aUS$64.48m
KPRX Kiora Pharmaceuticals
1.8x-40.4%US$10.16m
ORMP 20.9xIndustry Avg. 19.3xNo. of Companies12PE01224364860+
12 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: ORMP is expensive based on its Price-To-Earnings Ratio (20.9x) compared to the US Pharmaceuticals industry average (20.1x).

Price to Earnings Ratio vs Fair Ratio

What is ORMP's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

ORMP PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio20.9x
Fair PE Ratio0.9x

Price-To-Earnings vs Fair Ratio: ORMP is expensive based on its Price-To-Earnings Ratio (20.9x) compared to the estimated Fair Price-To-Earnings Ratio (0.9x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

ANI Pharmaceuticals

US$1.1b

A biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada.

ANIP

US$55.86

7D

-5.2%

1Y

8.0%

Teva Pharmaceutical Industries

US$19.3b

Develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally.

TEVA

US$17.08

7D

2.0%

1Y

80.5%

Collegium Pharmaceutical

US$967.5m

A specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management.

COLL

US$30.41

7D

0.5%

1Y

17.1%